Celadon Pharmaceuticals Plc (AIM: CEL)
London
· Delayed Price · Currency is GBP · Price in GBX17.54
-0.86 (-4.67%)
Nov 20, 2024, 10:39 AM GMT+1
Celadon Pharmaceuticals Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Aug '20 Aug 31, 2020 | 2019 |
| Revenue | 0.13 | 0.08 | 0.02 | 0 | - | - | Upgrade
|
| Revenue Growth (YoY) | 519.05% | 212.50% | 1100.00% | - | - | - | Upgrade
|
| Cost of Revenue | 0.09 | 0.07 | 0.09 | 0.01 | - | - | Upgrade
|
| Gross Profit | 0.04 | 0 | -0.07 | -0.01 | - | - | Upgrade
|
| Selling, General & Admin | 4.92 | 5.47 | 4.85 | 2.38 | 0.5 | 0.14 | Upgrade
|
| Research & Development | - | - | - | - | 0.22 | - | Upgrade
|
| Other Operating Expenses | -0.41 | -0.07 | - | - | -0 | - | Upgrade
|
| Operating Expenses | 4.97 | 6.22 | 12.85 | 2.7 | 0.72 | 0.14 | Upgrade
|
| Operating Income | -4.93 | -6.22 | -12.92 | -2.71 | -0.72 | -0.14 | Upgrade
|
| Interest Expense | -0.59 | -0.58 | -4.04 | -0.65 | -0.34 | - | Upgrade
|
| Interest & Investment Income | 0.01 | 0.03 | 0.01 | - | 0 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0.02 | 0.29 | -0.66 | - | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | -5.52 | -6.78 | -16.65 | -4.02 | -1.06 | -0.17 | Upgrade
|
| Merger & Restructuring Charges | -0.74 | -0.74 | -1.47 | -0.78 | - | - | Upgrade
|
| Pretax Income | -5.49 | -7.52 | -18.12 | -4.8 | -1.06 | -0.17 | Upgrade
|
| Income Tax Expense | -0.26 | -0.26 | -0.71 | -0.01 | - | - | Upgrade
|
| Earnings From Continuing Operations | -5.23 | -7.26 | -17.41 | -4.78 | -1.06 | -0.17 | Upgrade
|
| Minority Interest in Earnings | - | 0.12 | 0.41 | 0.16 | - | - | Upgrade
|
| Net Income | -5.23 | -7.14 | -17.01 | -4.63 | -1.06 | -0.17 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 0.01 | - | - | Upgrade
|
| Net Income to Common | -5.23 | -7.14 | -17.01 | -4.64 | -1.06 | -0.17 | Upgrade
|
| Shares Outstanding (Basic) | 63 | 62 | 57 | 44 | 0 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 62 | 57 | 44 | 0 | 6 | Upgrade
|
| Shares Change (YoY) | 2.69% | 8.03% | 29.26% | 143913.21% | -99.50% | - | Upgrade
|
| EPS (Basic) | -0.08 | -0.12 | -0.30 | -0.10 | -34.43 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.08 | -0.12 | -0.30 | -0.10 | -34.43 | -0.03 | Upgrade
|
| Free Cash Flow | -5.74 | -6.31 | -8.19 | -3.69 | -0.79 | -0.16 | Upgrade
|
| Free Cash Flow Per Share | -0.09 | -0.10 | -0.14 | -0.08 | -25.53 | -0.03 | Upgrade
|
| Gross Margin | 30.00% | 1.33% | -275.00% | - | - | - | Upgrade
|
| Operating Margin | -3793.85% | -8288.00% | -53820.83% | -135650.00% | - | - | Upgrade
|
| Profit Margin | -4024.62% | -9520.00% | -70858.33% | -232050.00% | - | - | Upgrade
|
| Free Cash Flow Margin | -4418.46% | -8417.33% | -34108.33% | -184500.00% | - | - | Upgrade
|
| EBITDA | -4.55 | -5.85 | -12.59 | -2.49 | -0.66 | - | Upgrade
|
| D&A For EBITDA | 0.39 | 0.37 | 0.33 | 0.22 | 0.06 | - | Upgrade
|
| EBIT | -4.93 | -6.22 | -12.92 | -2.71 | -0.72 | -0.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.